Key terms
About SLS
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLS news
Yesterday
7:06am ET
Sellas Life Sciences-licensed GFH009 included in trial combination for lymphoma
Mar 27
2:25pm ET
Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
Mar 27
8:46am ET
Largest borrow rate increases among liquid names
Mar 22
8:46am ET
Largest borrow rate increases among liquid names
Mar 21
2:50pm ET
Sellas Life Sciences options imply 20.1% move in share price post-earnings
Mar 15
9:08am ET
Sellas prices 13.03M shares at $1.535 in direct offering, private placement
Mar 14
2:34pm ET
Sellas Life Sciences options imply 12.0% move in share price post-earnings
Mar 08
4:23pm ET
SELLAS Life Sciences Announces Executive Shake-up and Reorganization Strategy
Mar 08
8:11am ET
Sellas Life announces departure of CCO Francomano, General Counsel Wood
Mar 07
8:45am ET
Largest borrow rate increases among liquid names
Mar 06
8:45am ET
Largest borrow rate increases among liquid names
Mar 04
8:45am ET
Largest borrow rate increases among liquid names
Mar 01
8:35am ET
Sellas Life Sciences delivers oral presentation of SLS009 Phase 1 data
Feb 29
8:27am ET
Sellas Life Sciences to present SLS009 Phase 1 data ay 2024 ESH
Feb 26
8:45am ET
Largest borrow rate increases among liquid names
Feb 16
4:28pm ET
SELLAS Life Sciences Faces Nasdaq Minimum Bid Price Warning
Feb 08
7:07am ET
Sellas price target lowered to $7.50 from $8 at Alliance Global Partners
Feb 06
8:32am ET
Sellas Life Sciences announces publication of preclinical data on SLS009
Jan 10
12:15pm ET
Buy Rating Affirmed for SELLAS Life Sciences Amidst Promising Drug Development and Strategic Financing
Jan 09
8:33am ET
Sellas Life Sciences receives FDA fast track designation for SLS009
Jan 04
9:09am ET
Sellas Life Sciences prices 12M shares at 75c in public offering
Jan 03
8:12pm ET
Sellas Life Sciences announces proposed public offering of common stock
Jan 03
7:35am ET
Sellas Life Sciences provides corporate update
No recent news articles are available for SLS
No recent press releases are available for SLS
SLS Financials
Key terms
Ad Feedback
SLS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range